Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe De Block

Showing results (101-110 of 141) with videos related to

Pageof 15
Sort By:
Journal of Clinical Medicine|August 23, 2020
Mobile-Based Lifestyle Intervention in Women with Glucose Intolerance after Gestational Diabetes Mellitus (MELINDA), A Multicenter Randomized Controlled Trial: Methodology and DesignCaro Minschart, Toon Maes, Christophe De Block, et al.
European Journal of Endocrinology|May 19, 2023
Weight retention and glucose intolerance in early postpartum after gestational diabetesCaro Minschart, Nele Myngheer, Toon Maes, et al.
Lancet (London, England)|June 5, 2021
Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trialMargaretha M Visser, Sara Charleer, Steffen Fieuws, et al.
Plos One|December 2, 2016
Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide RatioAnnelien Van Dalem, Simke Demeester, Eric V Balti, et al.
The Lancet. Diabetes & Endocrinology|January 26, 2023
Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trialMargaretha M Visser, Sara Charleer, Steffen Fieuws, et al.
Journal of Diabetes Science and Technology|September 29, 2022
The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes: Moderator Analyses of the ALERTT1 TrialMargaretha Martha Visser, Sara Charleer, Steffen Fieuws, et al.
Plos One|June 2, 2017
Correction: Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide RatioAnnelien Van Dalem, Simke Demeester, Eric V Balti, et al.
Pituitary|March 27, 2013
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension studyStephan Petersenn, Andrew J Farrall, Christophe De Block, et al.
Acta Diabetologica|November 20, 2020
Predictors of neonatal adiposity and associations by fetal sex in women with gestational diabetes mellitus and normal glucose-tolerant womenKatrien Benhalima, Anaïs De Landtsheer, Paul Van Crombrugge, et al.
The Journal of Clinical Endocrinology and Metabolism|November 19, 2014
Hyperglycemic clamp and oral glucose tolerance test for 3-year prediction of clinical onset in persistently autoantibody-positive offspring and siblings of type 1 diabetic patientsEric V Balti, Evy Vandemeulebroucke, Ilse Weets, et al.
Pageof 15

Showing results (101-110 of 141) with videos related to

Sort By:
Pageof 15
Journal of Clinical Medicine|August 23, 2020
Mobile-Based Lifestyle Intervention in Women with Glucose Intolerance after Gestational Diabetes Mellitus (MELINDA), A Multicenter Randomized Controlled Trial: Methodology and DesignCaro Minschart, Toon Maes, Christophe De Block, et al.
European Journal of Endocrinology|May 19, 2023
Weight retention and glucose intolerance in early postpartum after gestational diabetesCaro Minschart, Nele Myngheer, Toon Maes, et al.
Lancet (London, England)|June 5, 2021
Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trialMargaretha M Visser, Sara Charleer, Steffen Fieuws, et al.
Plos One|December 2, 2016
Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide RatioAnnelien Van Dalem, Simke Demeester, Eric V Balti, et al.
The Lancet. Diabetes & Endocrinology|January 26, 2023
Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trialMargaretha M Visser, Sara Charleer, Steffen Fieuws, et al.
Journal of Diabetes Science and Technology|September 29, 2022
The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes: Moderator Analyses of the ALERTT1 TrialMargaretha Martha Visser, Sara Charleer, Steffen Fieuws, et al.
Plos One|June 2, 2017
Correction: Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide RatioAnnelien Van Dalem, Simke Demeester, Eric V Balti, et al.
Pituitary|March 27, 2013
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension studyStephan Petersenn, Andrew J Farrall, Christophe De Block, et al.
Acta Diabetologica|November 20, 2020
Predictors of neonatal adiposity and associations by fetal sex in women with gestational diabetes mellitus and normal glucose-tolerant womenKatrien Benhalima, Anaïs De Landtsheer, Paul Van Crombrugge, et al.
The Journal of Clinical Endocrinology and Metabolism|November 19, 2014
Hyperglycemic clamp and oral glucose tolerance test for 3-year prediction of clinical onset in persistently autoantibody-positive offspring and siblings of type 1 diabetic patientsEric V Balti, Evy Vandemeulebroucke, Ilse Weets, et al.
Pageof 15